Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway

International Journal of Oncology

Volumn 48, Issue 5, 2016, Pages 2063-2070

  Chen, Jie Ru ^a   Jia, Xiu Hong ^a   Wang, Hong ^a   Yi, Ying Jie ^a   Wang, Jian Yong ^a   Li, You Jie ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

MRP1; Multidrug resistance; P gp; PI3K Akt signaling pathway; Reverse; Timosaponin A III

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SAPONIN DERIVATIVE; TIMOSAPONIN A; UNCLASSIFIED DRUG; WORTMANNIN; ABCB1 PROTEIN, HUMAN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SAPONIN; STEROID; TIMOSAPONIN AIII;

ANEMARRHENA ASPHODELOIDES; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SAPONINS; SIGNAL TRANSDUCTION; STEROIDS;

EID: 84962575844     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3423     Document Type: Article

References (37)

1. Rodrigues AS, Dinis J, Gromicho M, Martins C, Laires A and Rueff J: Genomics and cancer drug resistance. Curr Pharm Biotechnol 13: 651-673, 2012.
2. Zhang X, Dong W, Zhou H, Li H, Wang N, Miao X and Jia L: a-2, 8-Sialyltransferase is involved in the development of multidrug resistance via PI3K/Akt pathway in human chronic myeloid leukemia. IUBMB Life 67: 77-87, 2015.
3. Kalle AM, Sachchidanand S and Pallu R: Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res 34: 1132-1138, 2010.
4. Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1. PLoS One 9: e85113, 2014.
5. Cheng Z, Yang N, Liang W, Yan X, Li L and Pan L: Effect of PTEN gene transfection on the reversal of multidrug resistance in K562/ADM cells. Leuk Lymphoma 53: 1383-1389, 2012.
6. Dharmapuri G, Doneti R, Philip GH and Kalle AM: Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways. Leuk Res 39: 696-701, 2015.
7. Kang Q and Yan S: Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells. Exp Ther Med 9: 1345-1350, 2015.
8. Zhang Z, Xu K, Bi Y, Yu G, Wang S, Qi X and Zhong H: Low intensity ultrasound promotes the sensitivity of rat brain glioma to doxorubicin by downregulating the expressions of P-glucoprotein and multidrug resistance protein 1 in vitro and in vivo. PLoS One 8: e70685, 2013.
9. Barrett D, Brown VI, Grupp SA and Teachey DT: Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs 14: 299-316, 2012.
10. Sheng Z, Ma L, Sun JE, Zhu LJ and Green MR: BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 118: 2840-2848, 2011.
11. Li Q, Wu Y, Fang S, Wang L, Qi H, Zhang Y, Zhang J and Li W: BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immunomodulatory function of hemangioblasts. Cancer Gene Ther 22: 227-237, 2015.
12. Wang Z, Yang L, Xia Y, Guo C and Kong L: Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway. Biol Pharm Bull 38: 277-284, 2015.
13. Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 30: 773-782, 2013.
14. Tsou SH, Chen TM, Hsiao HT and Chen YH: A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. PLoS One 10: e0116747, 2015.
15. Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 4: e923, 2013.
16. Lee B, Jung K and Kim DH: Timosaponin AIII, a saponin isolated from Anemarrhena asphodeloides, ameliorates learning and memory deficits in mice. Pharmacol Biochem Behav 93: 121-127, 2009.
17. Lim SM, Jeong JJ, Kang GD, Kim KA, Choi HS and Kim DH: Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance. Int Immunopharmacol 25: 493-503, 2015.
18. Lee B, Trinh HT, Jung K, Han SJ and Kim DH: Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritus. Immunopharmacol Immunotoxicol 32: 357-363, 2010.
19. Kimura M, Kimura I and Chem FJ: Combined potentiating effect of byakko-ka-ninjin-to, its constituents, rhizomes of Anemarrhena asphodeloitles, timosaponin A-III, and calcium on pilocarpine-induced saliya secretion in streptozocin-diabetic mice. Biol Pharm Bull 19: 926-931, 1996.
20. Tang YH, Sun ZL, Fan MS, Li ZX and Huang CG: Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice. Planta Med 78: 18-23, 2012.
21. Lok CN, Sy LK, Liu F and Che CM: Activation of autophagy of aggregation-prone ubiquitinated proteins by timosaponin A-III. J Biol Chem 286: 31684-31696, 2011.
22. Kang YJ, Chung HJ, Nam JW, Park HJ, Seo EK, Kim YS, Lee D and Lee SK: Cytotoxic and antineoplastic activity of timosaponin A-III for human colon cancer cells. J Nat Prod 74: 701-706, 2011.
23. Wang YZ, Feng B, Huang HZ, Kang LP, Cong Y, Zhou WB, Zou P, Cong YW, Song XB and Ma BP: Glucosylation of steroidal saponins by cyclodextrin glucanotransferase. Planta Med 76: 1724-1731, 2010.
24. Huang HL, Chiang WL, Hsiao PC, Chien MH, Chen HY, Weng WC, Hsieh MJ and Yang SF: Timosaponin AIII mediates caspase activation and induces apoptosis through JNK1/2 pathway in human promyelocytic leukemia cells. Tumour Biol 36: 3489-3497, 2015.
25. Wang S, Wang S, Wang C, Chen Y, Li J, Wang X, Wang D, Li Z, Peng Z and Fan L: Upregulation of multidrug resistanceassociated protein 1 by Allyl isothiocyanate in human bronchial epithelial cell: Involvement of c-Jun N-terminal kinase signaling pathway. Oxid Med Cell 2015: 903782, 2015.
26. Wang L, Meng Q, Wang C, Liu Q, Peng J, Huo X, Sun H, Ma X and Liu K: Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-κB signaling inhibition. J Nat Prod 76: 909-914, 2013.
27. Wang H, Wang X, Li Y, Liao A, Fu B, Pan H, Liu Z and Yang W: The proteasome inhibitor bortezomib reverses P-glycoproteinmediated leukemia multi-drug resistance through the NF-B pathway. Pharmazie 67: 187-192, 2012.
28. Xu X, Zhang Y, Li W, Miao H, Zhang H, Zhou Y, Li Z, You Q, Zhao L and Guo Q: Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol 92: 220-234, 2014.
29. Sinclair A, Latif AL and Holyoake TL: Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 169: 1693-1707, 2013.
30. Lage H: An overview of cancer multidrug resistance: A still unsolved problem. Cell Mol Life Sci 65: 3145-3167, 2008.
31. Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE and Maia RC: Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom 80B: 158-166, 2011.
32. Sy LK, Yan SC, Lok CN, Man RY and Che CM: Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res 68: 10229-10237, 2008.
33. Wang N, Feng Y, Zhu M, Siu FM, Ng KM and Che CM: A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma. Biochim Biophys Acta 1833: 2890-2899, 2013.
34. King FW, Fong S, Griffin C, Shoemaker M, Staub R, Zhang YL, Cohen I and Shtivelman E: Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PLoS One 4: e7283, 2009.
35. Gao F, Liu J, Dong WW, Wang W, Wang Y, Cai D, Zheng Z and Sun K: Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells. Oncol Rep 31: 926-932, 2014.
36. Wang R, Shao F, Liu Z, Zhang J, Wang S, Liu J, Liu H, Chen H, Liu K, Xia M, et al: The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondriadependent pathways. Chem Biol Interact 205: 1-10, 2013.
37. Zhu X, Wang L, Zhang B, Li J, Dou X and Zhao RC: TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. J Biochem 149: 405-414, 2011.